Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.

Wick, M C; Ernestam, S; Lindblad, S; Bratt, J; Klareskog, L; van Vollenhoven, R F

Wick, M C; Ernestam, S; Lindblad, S; Bratt, J; Klareskog, L; van Vollenhoven, R F.

Affiliation

Wick MC; Department of Rheumatology, Karolinska University Hospital, Solna, Sweden.

Scand J Rheumatol ; 34(5): 353-8, 2005.

Article in En | MEDLINE | ID: mdl-16234182

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antirheumatic Agents/therapeutic use; Arthritis, Rheumatoid/drug therapy; Immunoglobulin G/therapeutic use; Receptors, Tumor Necrosis Factor/therapeutic use; Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic/drug therapy; Drug Resistance; Etanercept; Humans; Infliximab; Middle Aged; Registries; Sweden; Treatment Failure; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Immunoglobulin G / Receptors, Tumor Necrosis Factor / Antirheumatic Agents / Antibodies, Monoclonal Limits: Adult / Aged / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Scand J Rheumatol Year: 2005 Document type: Article Affiliation country: Sweden

Search on Google

Add to My VHL

XML

PubMed Links